glp 1 peptide injections Glucagon-Like Peptide-1 (GLP-1) Agonists: Decreasing Waistlines, Increasing Poison Center Cases GLP-1 Key Facts

Tveit, M

Introduction Starting a weight loss journey often involves navigating a new landscape of medications and how they interact with your existing routine

10.1038/s41467-024-52898-y 127 SchulingkampR

According to Cullaro et al., in their complete review of national registry data, there was a 187% increase in the proportion of patients with cirrhosis and CKD at the time of liver transplant between 2002 and 2017. Furthermore, they reported, CKD at transplant was associated with a 16% independent higher risk of mortality post-liver transplant after adjusting for factors such as recipient age, etiology of cirrhosis, ethnicity, hepatic encephalopathy, era of transplant, diabetes mellitus, and donor risk index. This demonstrates the rising prevalence of CKD and its detrimental effects on patients undergoing liver transplantation

This means that the FDA does not verify the safety, efficacy, or quality of compounded semaglutide